or Try an Advanced Search...

    Technical Analysis for KROS - Keros Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 12.48 -2.65% -0.34
    KROS closed down 2.65 percent on Tuesday, January 14, 2025, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical KROS trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Narrow Range Bar Range Contraction 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -2.65%
    Older End-of-Day Signals for KROS ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 9 hours ago
    New 52 Week Low about 9 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    Down 3% about 10 hours ago
    Down 2 % about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    KROS Chart by TradingView

    Profile

    Keros Therapeutics, Inc. Description

    Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Organ Systems Bone Rare Diseases Disorders Hypertension Therapeutic Products Hematology Anemia Pulmonary Arterial Hypertension Myelodysplastic Syndrome Osteoporosis Syndromes Genodermatoses Skeletal Disorders Bone Disease Molecule Product Thrombocytopenia Myelofibrosis Hematopathology Musculoskeletal Disorders Osteogenesis Imperfecta

    Is KROS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Dec 18 Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share
    Dec 18 Keros Therapeutics: Hold Through The Dust
    Dec 14 Keros Therapeutics price target raised to $28 from $11 at Wells Fargo
    Dec 12 Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff
    Dec 12 Keros Therapeutics Prospects Still Strong Despite Cibotercept Hurdles, Wedbush Says
    Dec 12 Keros stock plunges 76% on drug study halt over safety concerns
    Dec 12 Keros Plummets 77% After Unexpected Side Effects 'Shock' Its Lead Drug
    Dec 12 Keros Therapeutics Loses 75% Value In A Single Session - Here's Why
    Dec 12 Keros shares collapse on ‘unanticipated’ setback for lung disease drug
    Dec 12 Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
    See more KROS news...

    Comments

    Indicators

    Indicator Value
    52 Week High 73.0
    52 Week Low 12.215
    Average Volume 1,137,546
    200-Day Moving Average 50.28
    50-Day Moving Average 42.46
    20-Day Moving Average 16.21
    10-Day Moving Average 14.97
    Average True Range 2.43
    RSI (14) 20.63
    ADX 47.85
    +DI 13.85
    -DI 51.00
    Chandelier Exit (Long, 3 ATRs) 61.97
    Chandelier Exit (Short, 3 ATRs) 19.50
    Upper Bollinger Bands 19.52
    Lower Bollinger Band 12.90
    Percent B (%b) -0.06
    BandWidth 40.85
    MACD Line -8.46
    MACD Signal Line -9.47
    MACD Histogram 1.0034
    Fundamentals Value
    Market Cap 424.13 Million
    Num Shares 34 Million
    EPS -4.96
    Price-to-Earnings (P/E) Ratio -2.52
    Price-to-Sales 229097.34
    Price-to-Book 6.14
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.71
    Resistance 3 (R3) 13.76 13.40 13.51
    Resistance 2 (R2) 13.40 13.08 13.37 13.44
    Resistance 1 (R1) 12.94 12.89 12.76 12.89 13.37
    Pivot Point 12.58 12.58 12.49 12.55 12.58
    Support 1 (S1) 12.12 12.26 11.94 12.07 11.59
    Support 2 (S2) 11.76 12.07 11.73 11.52
    Support 3 (S3) 11.30 11.76 11.46
    Support 4 (S4) 11.25